文献速递乳腺癌

早期乳腺癌中ERBB2低表达的预后与生物学意义

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
PubMed 文献 · JAMA Oncol · 2022-01-01

该队列研究纳入2016年1月至2021年3月在Dana-Farber Brigham癌症中心接受手术的5235例I-III期ERBB2阴性浸润性乳腺癌患者,比较ERBB2低表达与ERBB2-0肿瘤的临床病理特征和结局。结果显示ERBB2低表达与激素受体(HR)阳性更常见相关,ERBB2低表达比例随ER表达水平升高而增加;在HR阳性或三阴性乳腺癌中,ERBB2低表达与无病生存、远处无病生存或总生存均无差异。作者认为结果不支持将ERBB2低表达乳腺癌视为独立生物学亚型。

要点

  • ERBB2低表达肿瘤中HR阳性更常见(90.6% vs 81.8%,P < .001)
  • ERBB2低表达比例随ER表达水平升高而递增(P < .001)
  • HR阳性或三阴性乳腺癌中ERBB2低表达与生存结局无差异

核心结论

  • 该队列研究结果不支持将ERBB2低表达乳腺癌解释为独立的生物学亚型。
  • ERBB2低表达与ER表达水平正相关,ER低表达肿瘤在ERBB2-0肿瘤中富集,作者提示鉴于ER低表达肿瘤预后较差,其可能对ERBB2低表达的预后分析造成混杂。

研究设计与样本

  • 该队列研究使用Dana-Farber Brigham癌症中心前瞻性维护的机构数据库,纳入2016年1月至2021年3月期间接受手术的所有连续乳腺癌患者。
  • 研究纳入5235例I-III期ERBB2阴性浸润性乳腺癌患者,其中女性5191例(99.2%),初次手术时中位(范围)年龄为59.0(21.0-95.0)岁。
  • ERBB2免疫组化(IHC)评分为1+或2+且原位杂交阴性的肿瘤归类为ERBB2低表达,IHC评分为0归类为ERBB2-0。
  • 暴露为按机构指南进行的标准治疗;数据分析时间为2021年9月至2022年1月。

主要发现

  • 5235例患者中,ERBB2低表达2917例(55.7%),ERBB2-0为2318例(44.3%)。
  • ERBB2低表达肿瘤中HR表达显著更常见(2643例[90.6%] vs 1895例[81.8%],P < .001)。
  • ERBB2低表达肿瘤比例随ER表达水平升高而递增:ER阴性739例中296例(40.1%)、ER低表达(ER 1%-9%)67例中31例(46.3%)、ER中等表达(ER 10%-49%)67例中37例(55.2%)、ER高表达(ER 50%-95%)3542例中2047例(57.8%)、ER极高表达(ER > 95%)803例中499例(62.1%)(P < .001)。
  • 在接受新辅助化疗的675例患者中,ERBB2-0肿瘤患者病理完全缓解(pCR)率更高(95例[26.8%] vs 53例[16.6%],P = .002)。
  • 分别分析HR阳性、ER低表达、HR阳性且非ER低表达或三阴性乳腺癌时,ERBB2低表达与ERBB2-0肿瘤之间pCR率无统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 breast cancer. OBJECTIVE: To investigate whether low ERBB2 expression is associated with distinct clinicopathologic characteristics and prognosis among patients with hormone receptor (HR)-positive and triple-negative breast cancer (TNBC). DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted using data from a prospectively maintained institutional database on all consecutive patients with breast cancer undergoing surgery between January 2016 and March 2021 at Dana-Farber Brigham Cancer Center. The study included 5235 patients with stage I through III, ERBB2-negative invasive breast cancer. Tumors were classified as ERBB2-low if they had an ERBB2 immunohistochemical (IHC) score of 1+ or 2+ with negative in situ hybridization assay and ERBB2-0 if they had an ERBB2 IHC score of 0. Data were analyzed from September 2021 through January 2022. EXPOSURES: Standard treatment according to institutional guidelines. MAIN OUTCOMES AND MEASURES: Comparison of clinicopathologic characteristics and disease outcomes (pathologic complete response rate [pCR], disease-free survival, distant disease-free survival, and overall survival) between patients with ERBB2-low and ERBB2-0 breast cancer. RESULTS: Among 5235 patients with ERBB2-negative invasive breast cancer (5191 [99.2%] women; median [range] age at primary surgery, 59.0 [21.0-95.0] years), 2917 patients (55.7%) and 2318 patients (44.3%) had ERBB2-low and ERBB2-0 tumors, respectively. Expression of HR was significantly more common among ERBB2-low compared with ERBB2-0 tumors (2643 patients [90.6%] vs 1895 patients [81.8%]; P < .001). The rate of ERBB2-low tumors increased progressively, from 296 of 739 estrogen receptor (ER)-negative tumors (40.1%) to 31 of 67 ER-low (ie, ER 1%-9%) tumors (46.3%), 37 of 67 ER-moderate (ie, ER, 10%-49%) tumors (55.2%), 2047 of 3542 ER-high (ie, ER, 50%-95%) tumors (57.8%), and 499 of 803 ER-very high (ie, ER > 95%) tumors (62.1%) (P < .001). Among 675 patients receiving neoadjuvant chemotherapy, those with ERBB2-0 tumors experienced higher pCR rates (95 patients [26.8%] vs 53 patients [16.6%]; P = .002). However, there were no statistically significant differences in pCR rate between ERBB2-low and ERBB2-0 tumors when separately analyzing HR-positive, ER-low, HR-positive without ER-low, or TNBC tumors. In exploratory survival analysis, no differences by ERBB2-low expression in disease-free survival, distant disease-free survival, or overall survival were observed among patients with HR-positive tumors or TNBC. CONCLUSIONS AND RELEVANCE: The results of this cohort study did not support the interpretation of ERBB2-low breast cancer as a distinct biologic subtype. ERBB2-low expression was positively associated with level of ER expression, and ER-low tumors were enriched among ERBB2-0 tumors, suggesting that, given the worse prognosis of ER-low tumors, they may be associated with confounding of prognostic analyses of ERBB2-low expression.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022. PMID: 35737367. doi:10.1001/jamaoncol.2022.2286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。